Home > Press > Arrowhead to Present at Upcoming Scientific Conferences
Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May.
Scheduled conference presentations include the following:
TIDES 2014 - Providence, RI, May 12-15
May 12, 2014 - An oral presentation titled, "Using Endosomal Escape Agents for siRNA Delivery in vivo," will be presented at the workshop entitled "In vivo Delivery of Therapeutic Oligonucleotides: Challenges, Considerations and Solutions," by David Lewis, Ph.D., Chief Scientific Officer
May 14, 2014 - An oral presentation titled, "Next Generation Dynamic Polyconjugates for siRNA Delivery in vivo," will be presented by Aaron Almeida, Ph.D., Senior Scientist II
10th International Symposium on Polymer Therapeutics - Valencia, Spain, May 19-21
May 19, 2014 - An oral presentation titled, "Polymer-Based Vehicles for siRNA Delivery in vivo," will be presented by David Rozema, Ph.D., Vice President, Chemistry
ASGCT 17th Annual Meeting - Washington, DC, May 21-24
May 21, 2014 - An oral presentation titled, "Development of an siRNA-Based Therapeutic for Chronic HBV Infection Using DPC Technology," will be presented by David Lewis, Ph.D., Chief Scientific Officer
####
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.
For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to
For more information, please click here
Contacts:
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
Investor Relations:
The Trout Group
Lauren Glaser
646-378-2972
Media:
Russo Partners
Martina Schwarzkopf, Ph.D.
212-845-4292
Copyright © Arrowhead Research Corporation
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Simulating magnetization in a Heisenberg quantum spin chain April 5th, 2024
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Events/Classes
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||